Despite the increasing evidence regarding MMP3, neither the selective inhibitor of MMP3 (UK370106) (115) or the generic MMP inhibitor (marimastat) (116) have been assessed in relation to restricting primary tumors or metastatic tumor growth in canine or human OSA, despite some trials in other tumor types. Here, MMP3 is linked to neoplasm.